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ImmunizationStudies were performed to induce cross-clade neutralizing antibodies (Abs) by testing various combinations
of prime and boost constructs that focus the immune response on structurally-conserved epitopes in the V3
loop of HIV-1 gp120. Rabbits were immunized with gp120 DNA containing a V3 loop characterized by the
GPGR motif at its tip, and/or with gp120 DNA with a V3 loop carrying the GPGQ motif. Priming was followed
by boosts with V3-fusion proteins (V3-FPs) carrying the V3 sequence from a subtype B virus (GPGR motif),
and/or with V3 sequences from subtypes A and C (GPGQ motif). The broadest and most consistent
neutralizing responses were generated when using a clade C gp120 DNA prime and with the V3B-FP boost.
Immune sera displayed neutralizing activity in three assays against pseudoviruses and primary isolates from
subtypes A, AG, B, C, and D. Polyclonal Abs in the immune rabbit sera neutralized viruses that were not
neutralized by pools of human anti-V3 monoclonal Abs. Greater than 80% of the neutralizing Abs were
speciﬁc for V3, showing that the immune response could be focused on a neutralizing epitope and that
vaccine-induced anti-V3 Abs have cross-clade neutralizing activity.Published by Elsevier Inc.IntroductionAlthough cell-mediated immunity (CMI) is crucial for control of
established viral infections, neutralizing antibodies (Abs) are essential
for reducing the infectivity of a virus inoculum and for neutralizing
virions released during early rounds of replication (Plotkin, 2008;
Robbins, Schneerson, and Szu, 1995). Humoral responses may also
facilitate the development of effector and memory T cells which are
needed to eliminate virus-infected cells and control the spread of
infection (Haigwood et al., 1996; Yamamoto et al., 2007).
To protect against viral infections, vaccines have been developed
using a multitude of methods: live attenuated viruses are used in
vaccines against measles, mumps, rubella, polio, and inﬂuenza;
inactivated viruses are also being used to immunize against polio
and inﬂuenza. Currently, replicating and non-replicating viral vectors
are being developed as the basis of various human vaccines, but none
has been licensed yet for use in humans. Other vaccine constructse, c/oVeteransAffairsHospital,
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Inc.include virus-like particles (VLPs), which are the basis of the vaccine
against human papilloma virus, viral proteins, which are used in the
hepatitis B vaccine, or DNA, which, by itself, has not yet been proven
effective as a vaccine construct (von Bubnoff, 2008). Several of these
types of vaccine constructs have been tested in animals and humans as
the basis of an HIV-1 vaccine. To date, none of these approaches has
been proven successful.
Because of the potential risk of infection with live attenuated or
inactivated HIV, these are not currently being actively developed for
human use, however, replicating and non-replicating viral vectors are
being studied; most have been used in attempts to induce CMI and do
not prevent infection or induce broadly neutralizing Abs in humans
(Cox et al., 2008; Hanke et al., 2007). The use of VLPs, proteins, and
DNA–the safest of the various modalities–is also being explored in
attempts to induce CMI and/or the critical but elusive broadly
neutralizing Ab response. To date, enveloped HIV-VLPs have induced
anti-HIV neutralizing Abs to only a limited number of viruses
(Buonaguro et al., 2007; Buonaguro et al., 2002; Crooks et al., 2007).
HIV envelope glycoproteins, the only modality which has been tested
in Phase III clinical trials, give little CMI, inadequate neutralizing Ab
responses, and have failed to protect (Gilbert et al., 2005). DNA, by
itself, also appears to be inadequate in terms of induction of
neutralizing Abs (Graham et al., 2006; Mulligan et al., 2006).
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have been used in prime/boost immunization protocols, e.g.,
recombinant canary pox+gp120 (Graham et al., 1998), DNA+
recombinant modiﬁed vaccinia Ankara (Mulligan et al., 2006), and
DNA+recombinant adenovirus vectors (Mascola et al., 2005). One of
the most successful prime/boost protocols has been the use of DNA as
a prime followed by protein as a boost. This regimen has proven to be
more effective than the use of either DNA or protein immunogens
alone and has been shown to induce both HIV-speciﬁc multifunctional
T cell responses and/or Abs capable of neutralizing primary isolates
(Bansal et al., 2008; Barnett et al., 1997; Beddows et al., 2005; Law et
al., 2007; Lu et al., 1998; Richmond et al., 1998; Vaine et al., 2008;
Zolla-Pazner et al., 2008). In these latter studies, the DNA and protein
generally were derived from one or several subtype B strains or from
multiple subtypes, and the neutralizing activity was narrowor capable
of neutralizing isolates from various HIV subtypes only at modest
titers.
In an attempt to induce anti-HIV neutralizing Abs of broader
reactivity, we recently used the DNA prime/protein boost approach
to focus the immune response on the V3 loop, a neutralizing epitope
in gp120. The V3 loop was chosen to target from among the several
known neutralizing envelope epitopes because, while exhibiting
extreme sequence variation, it is a structurally-conserved region of
the virus envelope (Cardozo et al., 2007; Rosen et al., 2006; Sharon
et al., 2003) and is required for interaction with the chemokine
receptors CCR5 and CXCR4 which serve as coreceptors for HIV (Hill
et al., 1997; Rizzuto et al., 1998; Trkola et al., 1996; Wang et al.,
1999). Moreover, the V3 region of gp120 is known to induce Abs in
humans that display broad neutralizing activity against strains
within and between various clades (Binley et al., 2004; Gorny et al.,
2004; Haynes et al., 2006; Krachmarov et al., 2005; Pantophlet et
al., 2007). To target Abs to V3, we immunized rabbits with gp120
DNA from one or more HIV subtypes and boosted with recombinant
fusion proteins bearing V3 loops of subtypes A, B and/or C (V3-FPs).
Initial studies demonstrated that immune sera neutralized three of
four primary isolates from subtypes B, CRF02_AG, and CRF011_cpx,
and neutralized V3 chimeric pseudoviruses (psVs) carrying the
consensus V3 sequences from subtypes A1, AG, B, CRF01_AE, and F
(Zolla-Pazner et al., 2008). The study described below was under-
taken to determine the extent of neutralizing activity against a
much larger panel of primary isolates and psVs and to establish if
different combinations of gp120 DNA priming constructs and
different V3 sequences inserted into V3-FPs could induce broader
neutralizing Ab responses.Table 1
Immunization regimena.
Immunizing Regimen DNA primeb at weeks 0, 2 and
a Two immunization experiments were performed. The groups shown above and below
b V3 sequences contained in priming and boosting constructs are shown below. V3-FPs
Variations in sequence from relevant consensus sequences are underlined, and the variatio
CA1 clade A1 env gp120 DNA prime (AR): CT
92BR025.9 clade C env gp120 DNA prime (CQ): C
V3A-FP derived from clade A strain 92UG037.08: C
V3B-FP derived from clade B strain JR-CSF: C
V3C-FP derived from clade C strain 93IN904: CResults
Immunogens and immunization protocols
In order to focus the immune response on the V3 region of gp120,
rabbits were ﬁrst immunized with gp120 DNA in order to prime
memory T and B cells for V3 and other epitopes in this envelope
glycoprotein. Animals were primed three times with codon-optimized
gp120 DNA derived from subtype A or subtype C HIV env genes
(Table 1). These genes were derived from primary isolate CA1 (an R5-
tropic strain of CRF011_cpx carrying a subtype A Env) and from
primary isolate 92BR025.9 (an R5-tropic strain of subtype C). The
former was chosen because it is immunologically representative of a
cluster of unrelated primary isolates from several strains (Nyambi
et al., 2000) and carries a V3 loop which is characterized by the GPGR
motif at the tip of the loop. The env gene of 92BR025.9 was chosen as
a representative of subtype C and carries the GPGQmotif at the tip of
the V3 loop (see sequences in footnote, Table 1).
In order to speciﬁcally stimulate Abs to V3, rabbits were boosted
twice with one or a combination of V3-FPs in which the V3 scaffold
was a truncated form of Murine Leukemia Virus (MuLV) gp70; this
triggers the proliferation and differentiation of the previously induced
V3-speciﬁc memory B cells generated by the prime. The V3-FPs were
constructed using a truncated form ofMuLV gp70with one of three V3
loops at its C-terminus as per previous work that had shown that such
molecules present the V3 epitope in its immunologically correct
conformation (Kayman et al., 1994). The three V3-FPs contained a V3
region fromeither a subtypeAvirus (V3A-FP), a subtypeBvirus (V3B-FP),
or a subtype C virus (V3C-FP) (see V3 sequences in footnote, Table 1).
In the ﬁrst set of experiments described here, the primewas varied
and the boost was held constant. Three rabbits were immunized in
each of four groups. Each group received a different priming
immunization: either an empty vector, gp120 subtype A DNA bearing
the GPGR V3 motif (AR), gp120 subtype C DNA bearing the GPGQ V3
motif (CQ), or a combination of AR and CQ DNAs. All animals in these
four groups received the same multivalent boost consisting of V3A-FP,
V3B-FP, and V3C-FP (see Table 1). Initial data derived using sera from
these animals were previously published (Zolla-Pazner et al., 2008).
Thenextexperiment consistedof an immunization regimen inwhich
the prime was held constant and the boost varied. For this, ﬁve rabbits
were immunized per group; each of the four groups was primed with
the gp120 subtype C DNA bearing the GPGQ V3 motif (CQ). Boosting of
each of the four groups consisted of administration of V3A-FP, V3B-FP, or
V3C-FP, or a combination of V3A-FP and V3C-FP (Table 1).4 Protein boostb at weeks 10 and 14
the dotted line were included in each of the experiments, respectively.
used for protein boosts were based on various V3 sequences fused to gp70 of MuLV.
n at the tip of the loop, position 18 (R/Q), is bolded.
RPNNNTRKGIHIGPGRAIYATGDIIGDIRQAHC
TRPNNNTRKSIRIGPGQAFYATGEIIGDIRQAHC
TRPNNNTRKSVRIGPGQTFYATGDIIGDIRQAHC
TRPSNNTRKSIHIGPGRAFYTTGEIIGDIRQAHC
TRPNNNTRKSIRIGPGQTFYATGDIIGDIRQAHC
84 S. Zolla-Pazner et al. / Virology 392 (2009) 82–93ELISA results
To test the ability of the different prime and boost regimens to
induce anti-V3 Abs, the sera of all rabbits were tested for reactivity
with a fusion protein consisting of the consensus sequences of the
clade B or clade C V3 loop fused to the Fc fragment of rabbit Ig (V3-rFc)
(Davis et al., 2009). The only common epitope between V3-rFc, the
prime, and the boosts, is the V3 portion, insuring that the only Abs
detected in this ELISA are speciﬁc for V3. The results are shown in
Fig. 1. In the top panels, we conﬁrm previous data showing that the
gp120 DNA prime signiﬁcantly enhances the immune response to V3
epitopes (Wang et al., 2005; Zolla-Pazner et al., 2008). The data shown
in the upper panels suggest that the CQ prime is stronger than either
the AR prime or the AR+CQ prime, but the differences are not
statistically signiﬁcant between these groups. In experiments where
the CQ prime was held constant and different V3-FPs were used for
boosts (lower panels), the V3B-FP induces the strongest and most
consistent response.
Neutralizing activity in immune rabbit sera against V3 chimeric
pseudoviruses
To assess the range of V3 diversity recognized by anti-V3 Abs
induced in the immunized rabbits, the neutralizing activity of the
immune sera was ﬁrst tested against a panel of V3 chimeric psVs
which were constructed using the env gene of SF162, a neutralization-
sensitive virus from subtype B in which the V3 loop is highly
accessible to Abs (Krachmarov et al., 2006). In these V3 chimeric psVs,Fig. 1. Titration of V3 binding Abs in the sera of immunized rabbits. Rabbit serawere tested in
curves are based on the average OD values (±SD) at each dilution from assays run in duplic
group is deﬁned in Table 1. Data from animals receiving different primes and the triple pro
receiving the same prime (CQ) and different boosts are shown in panels C and D.the V3 loop of SF162 was replaced with the consensus V3 sequences
from subtypes A1, B, C, F, H, CRF01_AE (E), and CRF02_AG (AG) (see
footnote, Fig. 2). Given the neutralization sensitivity of psVs carrying
the SF162 Env, the 90% geometric mean neutralizing titers (GMT90)
were assessed. The data conﬁrm previous studies (Wang et al., 2005;
Zolla-Pazner et al., 2008) showing that without a gp120 DNA prime,
the V3-FPs do not induce a strong or broad neutralizing Ab response
(see group –/ABC, Fig. 2). All other groups which received either the
AR and/or CQ DNA primes and protein boosts mounted immune
responses that include Abs capable of recognizing and mediating 90%
neutralization of psVs carrying the V3 loops of subtypes A1, AG, B, F
and E (Fig. 2). The groups that were primed with AR or AR+CQ had
weak responses to non-B V3 chimeric psVs. The strongest responses to
B and non-B V3 chimeric psVs were induced by groups primed with CQ
and boostedwith V3B-FP (CQ/B), V3A- and V3C-FPs (CQ/AC), or with all
three V3-FPs (CQ/ABC). Although 90% neutralizationwas not achieved
against V3 chimeric psVs carrying the consensus V3 sequences of
subtype C or H, the same groups that gave the strongest responses to
otherpsVs (CQ/B, CQ/AC andCQ/ABC) all achieved50%neutralizationof
V3C and V3H psVs (GMT50 values of 1:76–88; GMT50 values of 1:20–86,
respectively). Interestingly, the group that received the AR+CQ prime
displayed a generally weaker response than any of the groups that
received the CQ prime alone. This may be because only 18 µg of each
DNA prime per dose was administered to the AR+CQ group whereas
animals receiving only the CQ prime received 36 µg per dose. Thus,
using the gp120 DNA prime/V3-FP boost regimen, Abs that are capable
of recognizing the V3 loops frommultiple viral subtypes were induced,
and the CQ prime gave the broadest and strongest responses.ELISA for reactivity against V3B-rFc (PANELS A and C) or V3C-rFc (PANELS B and D). The
ate with sera from individual rabbits in each group. The immunization regimen for each
tein boost of V3A-, V3B- and V3C-gp70 are shown in panels A and B; data from animals
Fig. 2. Reciprocal 90% neutralizing titers (NT90) of immune rabbit sera vs. V3 chimeric pseudoviruses. Values represent NT90s for serum from each individual rabbit vs. each V3
chimeric psV, while colored boxes are coded to show the 90% geometric mean titer (GMT90) for each rabbit group vs. each V3 chimeric psV: red boxes denote GMT90 N1:1000; orange
boxes, titers 1:100–999; yellow boxes, titers 1:10–99, and white boxes, no neutralizing activity. Columns show neutralizing titers against V3 chimeric SF162 pseudoviruses carrying
the following consensus sequences of subtypes B, F, AE, A1, AG, C and H:
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subtype B was the most sensitive to neutralization regardless of
whether the prime or the boost contained a V3with the GPGRmotif of
subtype B (Fig. 2). This may imply that: a) the subtype B V3 loop bears
structural or physicochemical characteristics that allow it to best
adapt to the combining site of the induced V3 Abs, b) the backbone of
SF162 accommodates a clade B V3 loop better than the V3 loops of
other subtypes, or c) other unidentiﬁed factors enhance the relative
neutralization sensitivity of the V3B sequence. In contrast, the clade C-
bearing chimeric psV162 is quite resistant, a phenomenon that may be
related to the relative inﬂexibility of the clade C V3 region (T. Cardozo,
personal communication).
Neutralizing activity in immune rabbit sera against primary isolates
It is well documented in studies of HIV and other viruses that the
potency of neutralizing activity detected in immune sera depends on
the assay and the conditions used (Baldinotti et al., 1994; Dimmock,1993; Polonis et al., 2008; Vaine et al., 2008; Zolla-Pazner, 1996).
Therefore, additional neutralizing assays were used to interrogate the
activity of the rabbit immune sera. The second assay used assessed the
neutralizing activity of the rabbit immune sera against primary isolates
rather than psVs. For this, a panel of 15 primary isolates was selected
from viruses of subtypes A, AG, B and C in order to represent (a) a
spectrumof viral subtypes, and (b) a rangeofneutralization sensitivities
based on each virus's sensitivity to neutralization by a pool of anti-V3
monoclonal Abs (mAbs) derived from subjects infected with subtype B
or non-B viruses (see Materials and methods). Thus, the 15 primary
isolates were tested for their ability to be neutralized by mAb pools at
concentrations ≤50 µg/ml. As shown in Fig. 3A, two of these viruses
(from subtype B) were sensitive to both clade B-derived and non-clade
B-derived pools of anti-V3 mAbs with ND50 values of b2 µg mAb/ml.
Five viruses (from subtypes B, A and AG) were sensitive to only one of
the two mAb pools with a 50% neutralizing dose (ND50) between 0.05
and 12 µg/ml, and eight viruses (from subtypes A, AG, and C) were not
neutralized by either pool when tested at 50 µg mAb/ml.
Fig. 3.Neutralizing activity of mAbs and immune rabbit sera against primary isolates. (A) The 50% neutralizing doses (ND50, µg/ml) are shown for anti-V3 mAb pools composed of
mAbs from clade B and from non-clade B-infected individuals against each of 15 primary isolates from subtypes B, A, AG and C. Each mAb pool contained ﬁve anti-V3 mAbs. Red
boxes denote ND50 b2 µg/ml; orange boxes, ND50 between 10–20 µg/ml, white boxes, ND50 N50 µg/ml. (B and C) For each rabbit serum/virus combination, the reciprocal NT50
value is shown. Where no value is listed, 50% neutralization was not achieved at the lowest dilution tested, either 1:5 or 1:10. The prime and boost delivered to each group of
animals are shown as per designations speciﬁed in Table 1. The strength of the response by each group of rabbits to each virus is denoted by color: where reciprocal GMT50 values
for each immunization group/virus are N80, the box is shaded red; GMT50 values between 40 and 80 are shown in orange, between 10 and 39 are shown in yellow, and those b10
are shown in white.
86 S. Zolla-Pazner et al. / Virology 392 (2009) 82–93The GMT50 values of sera from responding animals in each group
are shown in Figs. 3B and C vs. each of the 15 viruses; the presence of
demonstrable neutralizing Abs in the serum of each animal is also
shown. Given that percent neutralization of immune serum is based
on pre-bleeds of the same animal (see Materials and methods), and
positive neutralization was based on achieving 50% neutralization
with a reproducible dose-response curves for individual sera vs. each
virus (see Fig. 4), 50% neutralization titers (NT50) for individual sera
and GMT50 values for each group ≥1:10 are highly signiﬁcant and
reproducible.
The results conﬁrm the requirement for the DNA prime and
show again that the broadest responses are induced with the CQ
prime. While the CQ prime with the triple protein boost gave less
breadth, the immune sera from the groups receiving the CQ prime
and either the V3B-FP, or V3C-FP, or V3A- and V3C-FP boosts
neutralized 61%, 63% and 55% of the serum/virus combinations
compared to 38% and 36% neutralization of serum/virus combina-
tions neutralized by animals primed with AR or AR+CQ gp120
(Fig. 2) (p=0.016, Fisher's exact test). Notably, sera from the
groups receiving the CQ prime and either the V3B-FP, V3C-FP, or
V3A- and V3C-FP boosts neutralized 13–14 of the 15 primary isolates
from subtypes B, A, AG and C (Fig. 2). These neutralized viruses
included those which were sensitive, moderately resistant, or
completely resistant to neutralization by anti-V3 mAb pools. Further
quantitative information on the serumneutralizing activity is provided
by the dose-response curves shown in Fig. 4 against primary isolates
tested with the serum from the rabbit in each group that gave the
strongest response.To determine whether the neutralizing Abs induced by these
immunogenswere directed against V3 epitopes, peptides representing
the V3 sequence of subtype B virus BaL and that of the subtype C V3
consensus were used to block neutralizing activity in sera against
subtype B virus BZ167 or CRF02_AG virus DJ263. For all sera tested,
where neutralization of these two viruses was demonstrable, a
minimum of 78% of neutralizing activity could be blocked by at least
one of the two peptides. In most cases, both peptides blocked N50% of
the neutralizing activity. These results are shown in Fig. 5 where the
inhibition of serum neutralizing activity in the presence of either the
BaLV3peptide or the consensus CV3peptide is calculated based on the
neutralizing activity in the presence of a scrambledV3 peptide. The BaL
and consensus C V3 peptides were approximately equivalent in their
ability to block neutralization of BZ167. Differential blocking of DJ263
neutralizing activity was noted by these two peptides, but no clear
pattern was discernable. Since a minimum of 78% of neutralizing
activity is blocked by at least one of the two peptides and since it is
highly probable that some overlap exists in the ability of the two
peptides to block the neutralizing Abs, it is not possible to calculate the
additive effects of the two peptides used in these experiments, but the
data indicate that the vast majority of the neutralizing activity was
directed against V3.
Neutralizing activity against pseudoviruses expressing the Envs of
patient-derived isolates
Using a third neutralization assay, 57 psVs were initially tested
with four pools of human anti-V3 mAbs derived from cells of subjects
Fig. 4. Dose-response neutralization curves of individual immune rabbit sera. The serum from one rabbit from each group listed in Table 1 is shown in each panel. Neutralization curves are shown for viruses DJ263 (subtype AG) (♦), BZ167
(subtype B) (■); BX08 (subtype B) (▴); VI313 (subtype A) (□), and 93MW960 (subtype C) (○). Serum dilutions are shown on the x-axis and percent neutralization is shown on the y-axis. Percent neutralization is based on the activity in the
immune sera vs. the corresponding animal's pre-immune serum at the same dilution. Data shown are from one of two or more experiments. The sera used were from the following rabbits (as identiﬁed in Figs. 2 and 3): Panel A=rabbit 18;
B=rabbit 21; C=rabbit 24; D=rabbit 26; E=rabbit 43; F=rabbit 50; G=rabbit 55; and H=rabbit 58.
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Fig. 5. Ability of V3 peptides to block serum neutralizing activity. Subtype B virus BZ167 (panels A and B) or CRF02_AG virus DJ263 (panels C and D) were tested for their ability to
be neutralized by sera diluted 1:20 or 1:60, respectively. Serum from each rabbit in each group was pre-incubated with 180 µg/ml of the subtype B BaL V3 peptide (hatched bars)
or the subtype C consensus V3 peptide (gray bars). The mean percent inhibition of neutralization by each peptide assessed for animals in each group is shown on the y-axis and is
based on neutralization of the same serum in the presence of 180 ug/ml of a scrambled V3 peptide. Data are from one of two experiments. Groups are designated as per Table 1. NN,
non-neutralizing.
Table 2
Characteristics of patients and viruses from which pseudoviruses were constructed.
Virus name Subtype Nature of infectiona Infection statusb
MB-SZP-3 B Heterosexual Acute
MB-SZP-8 B Heterosexual Acute
MB-SZP-9 B Heterosexual Acute
MB-SZP-12 B Heterosexual Acute
MB-SZP-28 B MSM Acute
MB-SZP-30 B MSM Acute
MB-SZP-32 A Unknown Unknown
MB-SZP-37 A Unknown Unknown
MB-SZP-52 C Unknown Unknown
MB-SZP-53 C Unknown Unknown
MB-SZP-54 C Unknown Unknown
MB-SZP-57 C Unknown Unknown
MB-SZP-61 C Unknown Unknown
MB-SZP-72 D Unknown Unknown
MB-SZP-76 D Unknown Unknown
MB-SZP-92 B Unknown Progressor
MB-SZP-100 B Unknown Progressor
MB-SZP-105 B Unknown LTNP
MB-SZP-106 B Unknown LTNP
MB-SZP-107 B Unknown LTNP
a MSM: men who have sex with men.
b LTNP: Long-term non-progressors (also deﬁned as “viremic controllers” who are
untreated and asymptomatic subjects infected for N7 years with viral loads between
50–200).
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tested, and the activity of each pool was assessed at a ﬁnal total
concentration of 50 µg mAbs/ml. Simultaneously, an HIV+ plasma
specimen with broadly neutralizing activity was titrated between
dilutions of 1:10–1:40,000. This plasma, Z23, had previously been
chosen from among 30 plasmas as showing the broadest neutralizing
activity against a panel of viruses. The 57 psVs were constructed from
the viral Envs derived from patients infected with subtype A, B, C or D.
Twenty of these psVs were selected for further study on the basis of
their neutralization sensitivity or resistance and on the diversity of
their origins from subjects infected acutely or chronically by different
routes and by different viral subtypes. Table 2 shows the charac-
teristics of the patients and viruses from which these 20 psVs were
constructed. Data generated with the 20 psVs are presented in Fig. 6
where they are ranked in order of their sensitivity to the pools of anti-
V3mAbs (from left to right). Thus, psV 92was themost sensitive since
its average level of neutralization by the four pools of anti-V3 mAbs
when tested at 50 µg/ml was 55%. Pseudovirus 3 was the least
sensitive to neutralization, being neutralized at an average level of 1%
by the four pools of anti-V3 mAbs at 50 µg/ml. For comparison, psVs
carrying the Envs of SF162, JR-CSF and NL43 were neutralized at
average levels of 100%, 65%, and 72%, respectively, by the four anti-V3
mAb pools at 50 µg/ml (data not shown) and the negative control
aMLV virus was not neutralized by any of the pools. Thirteen of the
20 psVs were neutralized to a signiﬁcant level by the pools of anti-V3
mAbs as deﬁned on the basis of the 95% conﬁdence limit established
with a pool of irrelevant human mAbs.
Fig. 6 also shows the reciprocal NT50 values at which each of the
20 psVs was neutralized by HIV+ plasma Z23. Based on its reactivity
with the aMuLV negative virus control, a positive neutralization titer
for Z23 is N1:200, accounting for its rather high background activity,and thus 14/20 psVs were neutralized by Z23 with ND50 values
reaching 1:916 (Fig. 6). For comparison, the NT50 values for Z23
against the psVs carrying the Envs of SF162, JR-CSF and NL43 were
1:21251,1:3532 and 1:360, respectively. Interestingly, therewere psVs
that were neutralized well by Z23 and poorly by the anti-V3 mAb
Fig. 6. Neutralizing activity of rabbit immune sera, anti-V3 mAb pools, and a broadly neutralizing HIV+ serum against pseudoviruses expressing the Envs of patient-derived isolates.
Twenty pseudoviruses carrying the Envs from clade A, B, C or D viruses were tested against immune sera from rabbits immunized with gp120 DNA from clade C and V3-FPs, as per
Table 1. The percent neutralization displayed by rabbit immune sera diluted 1:10 is shown against the 20 psVs as well as the negative control aMLV psV. While analysis of pre-bleed
sera indicates that neutralization of≥40% is statistically signiﬁcant (pb0.05), the more conservative convention is used in this ﬁgure where only serum/psV combinations achieving
50% neutralization are denoted by black squares. The same viruses were tested for neutralization by four anti-V3 mAb pools under conditions in which the ﬁnal concentration of
each pool of four mAbs was 50 µg mAbs/ml. The average percent neutralization by the four pools is shown, and viruses are listed, left to right, in terms of most to least sensitive to
anti-V3 mAb neutralization. Positive neutralization (deﬁned in the text) is demarcated by gray and black boxes. The same viruses were also tested for neutralization sensitivity to an
HIV+ serum, Z23. The 50% reciprocal neutralization titers (NT50) against each pseudovirus are shown. Positive neutralization (deﬁned in the text) is demarcated by gray and black
boxes.
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mAb pools and the HIV+ serum contain Abs of different speciﬁcities,
and that individual psVs vary in their sensitivities to these different Ab
speciﬁcities.
Using these 20 psVs, neutralizing activity was assessed by titration
of coded specimens consisting of the individual rabbit immune sera
drawn 2 weeks after the second boost; sera tested came from the
rabbits primed with CQ and boosted with V3A-FP, V3B-FP, V3C-FP, or
V3A- and V3C-FPs (see Table 1). Negative controls consisted of pools of
pre-bleed sera containing equal quantities of serum drawn prior to
immunization from the animals in each experimental group tested
against the 20 psVs, aMLV, and psVs carrying the Envs of JR-CSF, NL43
and SF162. In total, 120 assays were done with combinations of pre-
bleed pools and the various psVs. Analysis of the 95% conﬁdence limit
with the results of these negative control experiments indicates that
signiﬁcant neutralization was achieved when neutralization levels of
≥40% was achieved. In Fig. 6, the more stringent convention of 50%
neutralization is used to denote positive neutralization.
Notably, sera from the groups receiving the CQ prime and the V3B-FP
boost (CQ/B) neutralized 18 of the 20 psVs tested with sera diluted
1:10, and four of theﬁve animals neutralized 13 psVs fromsubtypesB, C
and D (Fig. 6). The proportion of viruses neutralized by sera from this
CQ/B group (i.e., positive serum/virus combinations tested for each
group) was 66% whereas the proportion of serum/psV combinations
neutralized by the other three groups ranged from 20–43%. When the
neutralizing potencies of sera in each group were compared by the
Kruskal–Wallis analysis with Dunnett's multiple comparison test
the CQ/B group was found to give signiﬁcantly stronger responses
than the other three groups (pb0.001) while there was no difference
among the other three groups.
The neutralizing activity in the sera of rabbits immunized with CQ/B
was broader than that displayed by the anti-V3 mAb pools as shown in
Fig. 6 where the psVs are ranked in order of neutralization sensitivity tothe anti-V3 mAb pools (left to right). The rabbit immune sera from the
CQ/B group neutralized 6 of 7 psVs that were not neutralized by the
mAb pools. Sera from this group of animals also neutralized 8 of 9 psVs
whoseneutralization sensitivity to anti-V3mAbpoolswas intermediate,
and neutralized all of the four psVs that were sensitive to anti-V3
neutralization. Thus, in four of ﬁve of the rabbits in this group,
immunization induced neutralizing Abs of greater breadth than that
shown by pools of human anti-V3 mAbs.
Discussion
An immunization protocol that focuses the immune response on
the structurally-conserved V3 epitope induced Abs in rabbits that
were capable of neutralizing psVs and primary isolates constructed or
isolated from subjects infected with HIV subtypes A, AG, B, C, and D.
These psVs and primary isolates were derived from patients whowere
acutely or chronically infected by heterosexual or homosexual
exposure. The neutralizing activity was assessed in three different
assays, run in three independent laboratories, and was shown by
peptide blocking experiments to be directed against V3 epitopes. The
immunization regimen that gave the most consistent and broadest
responses when assessed in all three assays was that in which the
animals were primed with subtype C gp120 DNA and boosted with
V3B-FP; the breadth of this response was greater than that displayed
by pools of human anti-V3 mAbs.
Given the variation in results achieved with different neutraliza-
tion assays and the challenges of standardizing a single assay for use in
several labs, the immune rabbit sera generated by the DNA prime/
protein boost protocols used here were tested against three different
groups of viruses and psVs in three different assays in three different
labs: (a) Clonal V3 chimeric psVs carrying the V3 sequences of various
subtypes presented in the context of the neutralization-sensitive
SF162 backbone were tested using the CD4+CCR5+ U87 line as target
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engineered CD4+CCR5+ TZM-bl line as target cells. And (c) psVs
constructedwith an uncloned panel of primary envelopes derived from
the plasma of HIV+ individuals were tested using the CD4+CCR5+
CXCR4+ U87 line as target cells. The latter assay was run on coded
samples. The data from all of these assay systems were consistent in
showing that priming with DNA containing a V3 sequence charac-
terized by the GPGQ motif at the tip was a better prime than a DNA
prime containing a V3 sequence carrying the GPGR motif. The
immunization regimen that gave the strongest and/or broadest
neutralizing Ab responses utilized the clade C gp120 DNA prime
together with boosts of the V3B-FP. Various combinations of V3A-,V3B-,
and/or V3C-FPs also induced cross-clade neutralizing Abs, although the
level and breadth of positive results from animals receiving the
combined V3-scaffold protein boosts were less reliably demonstrated
in all of the neutralization assays.
The demonstration that the CQ/B immunized group gave the
highest ELISA titers and the most consistent cross-clade neutralizing
Ab response reﬂects tenets in the classic immunologic literature
relevant to the induction of cross-reactive Abs. Thus, priming with
immunogen A and boosting with immunogen B is known to induce
Abs reactive with both immunogens (Richards et al., 1975). The data
presented above are also consistent with previously published data
that suggest that immunizing with constructs from more than one
clade of HIV induces broader immune responses than immunizing
with constructs from a single clade (Burke et al., 2009; Seaman et al.,
2005; Wang et al., 2006; Zolla-Pazner et al., 2008). However, the data
presented indicate that some combinations, e.g., CQ/B, are better than
others. Determining which prime and boost will give the optimal
qualitative response, i.e., Abs with the broadest neutralizing activity,
can be addressed rationally and informed by both structural and
immunologic studies of monoclonal Abs. However, it is noteworthy
that in the experiments described above the group receiving the
multivalent prime (see Table 1) did not give as strong or broad a
neutralizing response as the groups primed with the clade C gp120
alone. This quantitative effect of dose in multivalent vaccines needs
further study.
The level of neutralizing Abs achieved in these experiments varied
from 1:10–1:2400 depending on the assay system and the virus or psV
that was employed. V3 chimeric psVs carrying the Env of the
neutralization-sensitive SF162 virus were, not surprisingly, the most
sensitive (Fig. 2). Primary isolates known to be neutralization
sensitive, e.g., BX08, BZ167 and DJ263, gave the next highest titers,
with titers often N1:100 (Figs. 3 and 4). When more resistant viruses
and psVs (those often referred to as “Tier 2”) were tested, detectable
GMT50 values for neutralization Ab ranged from 1:10 to 1:102 (Figs. 3
and 6). Many of the primary isolates were in early passage after
isolation (NYU3738, NYU6525, NY129), and had only been grown in
PBMCs. Since such viruses aremore resistant than psVs when tested in
the TZM assay, these primary isolate neutralizing titers, which were
calculated on the basis of 2–3 titration experiments each run in
triplicate against a multiclade virus panel, are especially noteworthy.
The titers against “Tier 2” viruses and psVs are quantitatively
comparable or stronger, and qualitatively broader, than those recently
reported by others (Burke et al., 2009; Law et al., 2007; Mascola et al.,
2005; Morner et al., 2009; Seaman et al., 2005; Vaine et al., 2008; Wu
et al., 2006).
Protective levels of vaccine-induced serum neutralizing Abs
against polio have been reported at 1:4 (Plotkin, 2008) and ≥1:20
(Wicker et al., 2007). Similarly, vaccine-induced serum hemagglutinin
inhibitory Ab titers ≥1:40 are considered to be the protective
threshold for inﬂuenza (Hannoun et al., 2004). The relevance of
these values to protective Ab titers against HIV is open to question.
However, challenge with various strains of SHIV in passively
immunized macaques demonstrates that serum neutralizing titers of
1:1 (neat serum) to 1:38 can protect against infection (Hessell et al.,2009;Mascola et al., 2000; Shibata et al., 1999). Such low Ab titers that
confer protection suggest that previous conclusions about the need for
high Ab titers (Baba et al., 2000; Parren and Burton, 2001; Parren et al.,
2001) may be unwarranted. It is noteworthy that these data are
derived from experiments inwhich the challenging “animal infectious
dose” used induced infection in most or all control animals. In
contrast, infectious doses for human heterosexual transmission per
contact are on the order of one in 500 (Dunkle et al., 2008; Gray et al.,
2001). Given the requirements of experimental design in animal
studies to insure statistically meaningful results, the infectious doses
used in animal models appear to be orders of magnitude larger than
those occurring in humans. Thus, the level of Abs needed to protect
humans may be much less than that needed to protect animals that
are infected in most experimental models, and it is probable that the
level of Abs required to protect against natural human infection will
not be established until protection is achieved with a vaccine for
humans. Therefore, it is impossible to know whether the relatively
low vaccine-induced cross-clade neutralizing Ab titers which have
been reported by us and others would be protective. However, now
that considerable breadth has been achieved, additional experiments
using alternative adjuvants, vaccine formulations and delivery
systems should signiﬁcantly increase Ab levels, and thus achieve the
desired goal of inducing neutralizing Abs with a breadth and potency
capable of preventing infection with HIV.
While a yet-to-be-deﬁned minimal Ab titer is of critical signiﬁ-
cance for protection against infection, induction of Abs with broad
reactivity is an absolute requirement for any HIV vaccine candidate;
consequently, the aim of the experiments described here was to
increase the breadth of the neutralizing Ab response. One of the
variables examined to accomplish this was the nature of the prime.
Although the composition of gp120 molecules from clades B and C is
known to differ by ∼30%, one crucial difference which is especially
relevant to the induction of anti-V3 Abs occurs at the tip of the V3
loop, with the GPGRmotif characterizing most clade B viruses and the
GPGQ “tip type” occurring inmost clade C viruses. This R/Q distinction
has been shown to have considerable antigenic signiﬁcance in that the
R/Q mutation can alter neutralization sensitivity (Zolla-Pazner et al.,
2004). Similarly the R/Q difference between B and non-B clades
affects to the breadth of anti-V3 Abs produced by HIV-infected
individuals (Brown et al., 2008; Gorny et al., 2004; Gorny et al., 2006;
Krachmarov et al., 2006; Krachmarov et al., 2005). This R/Q difference
appears to have contributed to the broader anti-V3 Ab response
induced by the clade C gp120 DNA prime. This conclusion is supported
by the ﬁnding that mAbs that engage the R residue in the GPGR motif
at the tip of the V3 are quite restricted in their neutralizing activity for
viruses carrying the GPGR tip type (Binley et al., 2004; Stanﬁeld et al.,
2004; Zolla-Pazner et al., 2004). In contrast, anti-V3 mAbs where the
R/Q residue at the tip of V3 does not interact with the Ab surface are
able to neutralize both B and no-B clade viruses ((Stanﬁeld et al.,
2006) and unpublished data). The data suggest that the CQ prime
establishes memory for anti-V3 Abs that are independent of the V3 tip
type, and that, in the context of broadly reactive anti-V3memory cells,
the V3-FP boosts activate those memory B cells that are maximally
cross-reactive and capable of binding to both GPGR-containing and
GPGQ-containing V3 peptides and of neutralizing viruses from many
subtypes regardless of the motif at the tip of the V3 loop.
As shown in Fig. 3, the rabbits receiving the CQ prime and any one
of the V3-FPs produced Abs that could neutralize primary isolates that
were not neutralized by the anti-V3 mAbs pools. Thus, the polyclonal
Abs induced with a multiclade, V3-focused immunization protocol
showed broader neutralizing activity than cocktails of various anti-V3
monoclonal Abs. In neutralization assays for polyclonal Abs against
recombinant psVs constructed from the Envs of patients infected
acutely or chronically with various subtypes (Fig. 6), the group of
rabbits immunized with CQ/B gave the broadest response: 66% of the
100 serum/psV combinations were neutralized by the sera from the
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neutralized psVs from clades B, C and D. In contrast, several of the psVs
neutralized by the immune rabbit sera were neutralized poorly or
were entirely resistant to anti-V3 mAbs pools or to a broadly
neutralizing HIV+ human serum used as a positive control. Moreover,
four of ﬁve immune sera from the CQ/B group neutralized primary
isolates and psVs from subtypes A, AG, B, C and D in the various
neutralization assays performed in different labs (Figs. 2, 3 and 6).
Taking all of the data together, immunization with the CQ/B regimen
was shown to be capable of inducing the broadest, cross-clade
neutralizing Ab response.
Materials and methods
Use of codon-optimized HIV env DNA vaccine constructs
Codon-optimized env genes from HIV CRF011_cpx primary isolate
CA1 and clade C primary isolate 92BR025 were prepared as described
previously (Zolla-Pazner et al., 2008) and were chemically synthe-
sized by Geneart (Regensburg, Germany). The DNA vaccine plasmids
were prepared from Escherichia coli (HB101 strain) with a Mega
puriﬁcation kit (Qiagen, Valencia, CA) for in vivo animal immunization
studies.
Protein immunogens
The V3-FPs contain a 45-amino acid domain encompassing the V3
sequences of either JR-CSF (clade B), 92UG037.08 (clade A) or 93IN904
(clade C) (see footnote of Table 1). In addition to the V3 sequences,
these constructs included the ﬁve N-terminal and ﬁve C-terminal
amino acid residues that bracket V3, including the two terminal N-
linked glycosylation sites. The clade A and C proteins also contained a
synthetic TH epitope N-terminal to the V3, as previously described
(Kayman et al., 1994; Krachmarov et al., 2005). The insert is joined to
the C-terminus of a 263 amino acid fragment ofMuLV gp70, the V3-FPs
were synthesized in CHO cells, and all fusion proteins were puriﬁed on
Ni2+–nitrilotriacetic acid resin (NTA Superﬂow; Qiagen, Valencia, CA)
as described (Kayman et al., 1994; Krachmarov et al., 2001).
Immunization protocol
Female New Zealand white rabbits 6–8 weeks old (with a body
weight of ∼2 kg) were purchased fromMillbrook Farm (Amherst, MA)
and housed in the animal facility managed by the Department of
Animal Medicine at the University of Massachusetts Medical School in
accordance with an IACUC-approved protocol. Groups of rabbits
received three DNA immunizations at weeks 0, 2, and 4 using a Bio-
Rad Helios gene gun (Bio-Rad Laboratories, Hercules, CA). The gp120
DNAvaccine plasmids or the negative control pJW4303 vector plasmid
was coated onto 1.0 μm gold beads at a ratio of 2 μg of DNA per mg of
gold. Each gene gun shot delivered 1 μg of DNA to a total of 36 non-
overlapping sites on the shaved abdominal skin of each rabbit at each
of the three priming immunizations. The animals then received two
boosts with one or more of the V3-FPs at weeks 10 and 14 (Table 1). A
total of 100 μg/per injection of the V3-FP(s) was administered
intramuscularly with IFA. Blood was collected prior to immunization
and 2 weeks after each immunization.
ELISA assay
To determine the presence of anti-V3 Abs in immune rabbit sera,
ELISA binding studies were performed using U-bottom, 96-well
polyvinyl chloride plates (Falcon, Becton Dickinson). The V3B- or
V3C-rFC fusion proteins (Davis et al., 2009) were adsorbed at 2 μg/ml
to the wells for 2 h in 50 μl of carbonate buffer (pH=9.6) at 37 °C,
followed by blocking with 100 μl/well of 2.5% dry milk in phosphate-buffered saline (PBS) for 1 h. Serial three-fold dilutions of rabbit sera
were prepared in 2.5% dry milk/PBS and, after 2 h incubation at 37 °C,
bound serum Abs were detected with goat anti-rabbit Fab-speciﬁc,
alkaline phosphatase-conjugated secondary Abs (Zymed). Finally, the
substrate, p-nitrophenyl phosphate (Sigma) in 10% diethanolamine,
pH=9.8, was added, and plates were read at 405 nm.
Neutralization assays
Neutralization of primary isolates
JC53-BL cells (also termed TZM-bl cells) expressing CD4 and CCR5
and containing the Tat-responsive reporter genes for ﬁreﬂy luciferase
and E. coli β-galactosidase under the regulatory control of the HIV
long terminal repeat were obtained from the NIH AIDS Research and
Reference Reagent Program (NIH AIDS RRRP catalog no. 8129). These
cells were used to measure neutralizing activity of heat-inactivated
rabbit sera against primary isolates as previously described (Zolla-
Pazner et al., 2008) on the basis of the reduction in the luc reporter
gene expression after a single round of virus infection. Brieﬂy, 200
TCID50 of virus, produced in PHA-stimulated peripheral blood mono-
nuclear cells, was incubated with various dilutions of test serum or
anti-V3 mAb pools before addition to TZM-bl cells in the presence of
1 μM indinavir sulfate (NIH AIDS RRRP, catalog no. 8145). Virus
production was assessed after 48 h of incubation. The human anti-V3
mAb pools used in these experiments each contained ﬁve mAbs from
clade B-infected individuals from the US (clade B pool) or ﬁve mAbs
from non-clade B-infected individuals fromCameroon and India (non-
clade B pool). For peptide inhibition studies, a V3 peptide representing
either the V3 of the BaL2 strain (TRPNNNTRKSIHIGPGRAFYTTG),
consensus C (NNTRKSIRIGPGQTFYATGDIIG), or a scrambled V3
peptide (IGPGRATRPNNNFYTTGTRKSIH) was incubated for 30 min
at a ﬁnal concentration of 180 μg/ml with rabbit serum prior to its 1 h
incubation with 200 TCID50 of virus in culture medium. For all
experiments, background controls contained cells only, while the
virus controls contained cells plus virus. The percent neutralization for
immune rabbit sera was calculated relative to the effect of pre-
immune serum from the same rabbit. Thus, for all dilutions of sera, the
percent neutralizationwas calculated based on the RLU in the presence
of immune serum from a given animal divided by the RLU in the
presence of the same dilution of pre-immune serum from the same
animal. NT50 values for sera or ND50 values for mAb pools were
determined from the linear portion of the titration curves using the
method of Least Squares. Pairwise statistical comparison of differences
in the proportion of viruses neutralized by sera in different immuni-
zation groups was made by Fisher's exact test.
Neutralization of V3 chimeric pseudoviruses (psVs)
The infectious pseudotyped viruses were generated by co-
transfection of 293 cells with an env expression vector and with the
complementing vector pNL4-3.Luc.R-E- (NIH AIDS RRRP, catalog no.
3418, donated by Dr. Nathaniel Landau) (Connor et al., 1995; He et al.,
1995). The env expression vectors for chimeric forms of SF162 env
with various consensus V3 sequences were generated by introducing
the modiﬁcations sequentially by QuikChange site-directed mutagen-
esis (Stratagene, La Jolla, CA), as described (Krachmarov et al., 2006).
The V3 sequences inserted in place of the SF162 V3 are shown in the
footnote of Fig. 2. Only the sequences inside the V3 cysteines were
changed. Neutralizing activity was determined as previously
described (Krachmarov et al., 2001; Zolla-Pazner et al., 2008) with a
single-cycle infectivity assay using U87 cells expressing CCR5 and CD4
as target cells. GMT90 values of immune sera were determined by
interpolation from neutralization curves and are averages of at least
two independent assays; they were calculated by determining the
serum dilution at which RLUs were reduced 90% compared to control
wells containing virus alone. GMT90 values are calculated from two to
three assays of sera from each individual rabbit.
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patient-derived isolates
Env genes were extracted from viruses in patients' plasma,
ampliﬁed and used for preparation of psVs as previously described
(Schweighardt et al., 2007). Subsequently, the PhenoSense™ HIV
neutralization assay was run by Monogram Biosciences, Inc. on coded
rabbit sera. This assay, a single round recombinant assay, was used to
measure neutralization against 20 psVs as previously described
(Richman et al., 2003; Schweighardt et al., 2007). Brieﬂy, U87 cells
expressing CD4, CCR5 and CXCR4 were incubated with psV stocks
which had been pre-incubated with serial dilutions of mAb pools or
heat-inactivated rabbit immune sera. The ability of sera and mAbs to
neutralize virus was assessed by measuring luciferase activity 72 h
after psV inoculation in comparison to a control infection with virus
pseudotyped with the Env of MuLV (aMuLV). Four anti-V3 mAb pools
were tested for their ability to neutralize these 20 psVs. Each pool
contained four mAbs and was assessed at a ﬁnal concentration of
50 µg/ml; thus, each of the mAbs in each pool was present at a ﬁnal
concentration of 12.5 µg/ml. The data from these latter experiments
are expressed as the average percent neutralization of the given psV by
the four pools tested at a ﬁnal concentration of 50 µg mAbs/ml. The
mAb pools were assembled to include human anti-V3 mAbs from non-
clade B-infected individuals from Cameroon; from clade B-infected
individuals from the US, from non-B-infected individuals from
Cameroon and India, or from non-B and B-infected individuals from
the US and Cameroon. Pre-immune and immune rabbit sera and a
broadly neutralizing humanHIV+serum specimen (Z23)were titrated
to assess the presence of neutralizing activity. Data were analyzed by
the Kruskal–Wallis statistic using Dunnett's multiple comparison test
withoutmatchingandmakingnoassumption forGaussiandistribution.
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